MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
CONMED Corporation Book Value 2011-2026 | CNMD
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value CONMED Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.03 B | 963 M | 834 M | 746 M | 785 M | 709 M | 710 M | 662 M | 631 M | 581 M | 585 M | 581 M | 606 M | 607 M | 573 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 B | 573 M | 707 M |
Quarterly Book Value CONMED Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.01 B | 1 B | 978 M | 933 M | 882 M | 855 M | 796 M | 780 M | 752 M | 746 M | 716 M | - | 790 M | 785 M | 756 M | 744 M | 726 M | 709 M | 709 M | 709 M | 709 M | 710 M | 710 M | 710 M | 710 M | 662 M | 662 M | 662 M | 662 M | 631 M | 631 M | 631 M | 631 M | 581 M | 581 M | 581 M | 581 M | 585 M | 585 M | 585 M | 585 M | 581 M | 581 M | 581 M | 581 M | 606 M | 606 M | 606 M | 606 M | 607 M | 607 M | 607 M | 607 M | 573 M | 573 M | 573 M | 573 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.01 B | 573 M | 683 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B |  USA |
 |
AdaptHealth Corp.
AHCO
|
1.53 B | $ 13.08 | -2.24 % | $ 1.77 B | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M |  China |
 |
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | USA |
 |
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
50.1 M | $ 3.36 | 1.66 % | $ 126 M |  France |
 |
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | USA |
 |
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
28 M | $ 10.34 | -6.68 % | $ 293 M | USA |
 |
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.64 | 5.95 % | $ 39.8 M | USA |
 |
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | USA |
 |
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | USA |
 |
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
101 M | - | - | $ 10.2 M | USA |
 |
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M |  Canada |
 |
Electromed
ELMD
|
43.2 M | $ 25.1 | -2.49 % | $ 212 M | USA |
 |
Butterfly Network
BFLY
|
169 M | $ 4.92 | -4.47 % | $ 1.04 B | USA |
 |
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | USA |
 |
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
4.57 B | $ 87.79 | -3.25 % | $ 11.9 B | USA |
 |
Delcath Systems
DCTH
|
111 M | $ 10.21 | -3.22 % | $ 366 M | USA |
 |
Helius Medical Technologies
HSDT
|
2.35 M | $ 1.98 | -4.81 % | $ 1.2 M | USA |
 |
Inspire Medical Systems
INSP
|
781 M | $ 53.41 | -3.08 % | $ 1.57 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.75 B | $ 83.67 | -1.15 % | $ 2.91 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 81.22 | -1.29 % | $ 47.5 B | USA |
 |
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.03 | -0.96 % | $ 17.4 M | USA |
 |
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
347 M | $ 14.64 | -3.3 % | $ 343 M | USA |
 |
LivaNova PLC
LIVN
|
1.2 B | $ 58.92 | -3.87 % | $ 3.21 B |  Britain |
 |
LENSAR
LNSR
|
-12.2 M | $ 5.39 | 0.75 % | $ 64.5 M | USA |
 |
Pulmonx Corporation
LUNG
|
54.1 M | $ 1.2 | -2.04 % | $ 48.8 M | USA |
 |
MiMedx Group
MDXG
|
257 M | $ 3.09 | -9.26 % | $ 457 M | USA |
 |
Myomo
MYO
|
11.4 M | $ 0.79 | -3.54 % | $ 33.1 M | USA |
 |
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | USA |
 |
NanoVibronix
NAOV
|
33.5 M | - | - | $ 1.08 M | USA |
 |
NuVasive
NUVA
|
2.22 B | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
231 M | - | - | $ 217 M | USA |
 |
Orthofix Medical
OFIX
|
450 M | $ 11.49 | -3.53 % | $ 455 M |  Curacao |